ScienceDaily (May 16, 2007) — Recent evidence suggests that therapy currently used to treat Helicobacter pylori (H. pylori) infection, a major cause of upper gastrointestinal disorders, is unsuccessful in around 25 percent of cases. A new study, published in The American Journal of Gastroenterology, finds that adding a bovine protein called lactoferrin to the existing treatment may yield more effective results, with fewer of the side effects associated with common antibiotic treatment.

Lactoferrin has previously been found to be effective at inhibiting the growth of microorganisms and reducing the side effects of antibiotics, respectively, but the new study marks the first time that they have been used together to treat H. pylori. The study found that the infection-causing bacterium was eliminated in more patients treated with the traditional therapy plus lactoferrin than with the existing treatments and may be used without risk of resistance.

“Various studies are under way to evaluate new antibiotics and different therapeutic methods to increase the efficacy of H. pylori therapy,” says lead author Nicola de Bortoli, M.D., Ph.D., adding that “data suggest that antibiotic resistance is frequent and clinicians are realizing that use of an additional agent may be necessary for therapy.”

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Blackwell Publishing Ltd..

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Related Stories

Search ScienceDaily